Cost Management Insights: SG&A Expenses for AbbVie Inc. and MannKind Corporation

Navigating SG&A Expenses: A Tale of Two Companies

In the ever-evolving landscape of pharmaceuticals, cost management is crucial. AbbVie Inc. and MannKind Corporation, two prominent players, showcase contrasting strategies in managing Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AbbVie Inc. consistently demonstrated a robust approach, with SG&A expenses peaking at approximately $15.3 billion in 2022, reflecting a 98% increase from 2016. This growth underscores AbbVie's expansive operational scale and strategic investments.
Conversely, MannKind Corporation maintained a more conservative trajectory, with expenses hovering around $78 million annually, peaking at $108 million in 2015. This stability highlights MannKind's focused cost management, essential for its niche market operations.
Understanding these trends offers valuable insights into how different business models impact financial strategies, providing a roadmap for investors and industry analysts alike.